InspireMD Inc. - Common Stock (NSPR)
Frequently Asked Questions About InspireMD Inc. - Common Stock (NSPR)
How can investors learn more about InspireMD?
Investors can learn more about InspireMD by visiting the company's official website, where they can find recent news releases, financial reports, and presentations. Additionally, the company's filings with the Securities and Exchange Commission (SEC) provide valuable insights into financial performance and operational strategies, and investors can also participate in earnings calls and industry conferences for more information.
How does InspireMD handle product manufacturing?
InspireMD utilizes state-of-the-art manufacturing processes in line with strict regulatory standards to produce its innovative medical devices. The company ensures quality assurance throughout production by adhering to Good Manufacturing Practices (GMP) and continuously monitoring its supply chain to maintain high product quality and safety standards.
How does InspireMD's MicroNet™ technology work?
MicroNet™ technology is a proprietary design that integrates a polymeric mesh to protect against thrombus formation while maintaining optimal blood flow. This feature is particularly important in vascular stenting procedures as it helps reduce the risk of complications such as stroke. The MicroNet™ design differentiates InspireMD's stent offerings in terms of effectiveness and safety for patients.
How is InspireMD funded?
InspireMD has funded its operations through a combination of public offerings, private placements, and strategic financing arrangements. As a publicly traded company, it actively engages with investors to secure the necessary capital to support product development, marketing initiatives, and operational growth.
Is InspireMD involved in any partnerships?
Yes, InspireMD has formed strategic partnerships with various distributors, healthcare providers, and research institutions to broaden the market reach of its products. These partnerships are essential in facilitating clinical research, improving product visibility, and enhancing the company's ability to bring innovative solutions to the healthcare market.
On which stock exchange is InspireMD Inc. listed?
InspireMD Inc. trades on the Nasdaq stock exchange under the ticker symbol 'NSPR'. This listing provides the company with access to capital markets and allows investors to trade its shares, facilitating broader investor engagement and growth opportunities.
What are InspireMD's growth strategies?
InspireMD's growth strategies include expanding the clinical and commercial adoption of its CGuard™ Carotid Stent System, exploring opportunities for new product development, and pursuing strategic partnerships and collaborations. The company aims to enhance market access through clinical trials that demonstrate the effectiveness of its technologies and engage with healthcare stakeholders to build strong relationships.
What are the benefits of the CGuard™ system compared to traditional carotid stenting?
The CGuard™ system offers multiple benefits over traditional carotid stenting, mainly due to its MicroNet™ technology that provides a protective barrier against clots while allowing for safe blood flow. This design is intended to minimize the risk of stroke during and after the procedure, offering a potentially safer alternative for patients with a history of cardiovascular issues.
What challenges does InspireMD face?
InspireMD faces several challenges, including regulatory hurdles in new market entry, competition from established players in the medical device industry, and the need for continued clinical validation of its products. Additionally, the company must navigate market dynamics and shifts in healthcare policy that may affect reimbursement and pricing strategies.
What clinical studies has InspireMD conducted?
InspireMD has conducted various clinical studies to evaluate the efficacy and safety of its products, particularly the CGuard™ Carotid Stent System. These studies include pivotal trials and international registries aimed at accumulating real-world evidence of patient outcomes, effectiveness in diverse populations, and long-term safety data which ultimately supports regulatory approvals and market adoption.
What does InspireMD Inc. do?
InspireMD Inc. is a medical device company focused on developing and commercializing innovative solutions for vascular and interventional procedures. The company is best known for its CGuard™ Carotid Stent System, which is designed to reduce the risk of stroke for patients undergoing carotid artery interventions. By utilizing its proprietary MicroNet™ technology, InspireMD aims to improve patient outcomes through safer and more effective treatment options.
What is InspireMD's vision for the future?
InspireMD's vision is to become a leading player in the vascular medical device market by continually innovating and providing advanced solutions for interventional procedures. The company aims to enhance patient outcomes, reduce healthcare costs, and expand its portfolio to address a broader range of cardiovascular conditions, while increasing its global footprint in the medical device industry.
What is the CGuard™ Carotid Stent System?
The CGuard™ Carotid Stent System is InspireMD's flagship product, specifically designed for the treatment of carotid artery disease. This innovative device employs a unique MicroNet™ mesh that provides a protective barrier against thrombus formation. The CGuard™ enables physicians to perform carotid procedures with enhanced safety and efficacy, ultimately helping to reduce the incidence of stroke in at-risk patients.
What is the company's target patient population?
InspireMD's target patient population primarily includes individuals suffering from carotid artery disease, particularly those at high risk for stroke due to existing health complications. These patients often require effective interventions that can safely restore blood flow and reduce their risk of hemorrhagic events associated with carotid artery blockages.
What markets does InspireMD operate in?
InspireMD primarily operates in the vascular and interventional markets, focusing on medical devices related to cardiovascular diseases. The company's products are tailored for use in carotid artery procedures and are marketed towards hospitals and healthcare providers worldwide, aiming to expand its presence in both developed and emerging markets.
What regulatory approvals has InspireMD received?
InspireMD's key product, the CGuard™ Carotid Stent System, has received regulatory approvals from multiple international bodies, including the CE Mark in Europe, which allows the product to be sold in EU member states. The company continuously engages with regulatory authorities to ensure compliance and seek additional approvals for expanding its product lines.
What role does innovation play at InspireMD?
Innovation is central to InspireMD's mission and operational strategy. The company invests in research and development to discover and create groundbreaking medical technologies that address unmet clinical needs. By fostering a culture of innovation and collaboration, InspireMD seeks to lead advancements in vascular care and maintain its competitive edge in the market.
Where is InspireMD Inc. headquartered?
InspireMD Inc. is headquartered in Tel Aviv, Israel. The company's strategic location allows it to leverage a rich ecosystem of medical innovation and technology while maintaining global outreach through partnerships and collaborations in various healthcare markets.
Who are the key executives at InspireMD?
As of October 2023, InspireMD's executive leadership includes a team of professionals with extensive experience in the medical device and healthcare industries. The team is led by the CEO, who oversees strategic direction and operational performance, while other executives manage finance, operations, and product development to drive growth and innovation within the company.
What is the current price of InspireMD Inc. - Common Stock?
The current price of InspireMD Inc. - Common Stock is 1.350
When was InspireMD Inc. - Common Stock last traded?
The last trade of InspireMD Inc. - Common Stock was at 4:00 pm EDT on April 17th, 2026
What is the market capitalization of InspireMD Inc. - Common Stock?
The market capitalization of InspireMD Inc. - Common Stock is 57.20M
How many shares of InspireMD Inc. - Common Stock are outstanding?
InspireMD Inc. - Common Stock has 42.37M shares outstanding.